| Autor: |
Tam VH, Jumbe NL, Briceland LL, Miller MH |
| Zdroj: |
Journal of Infectious Disease Pharmacotherapy; 2001, Vol. 5 Issue 2, p11-20, 10p |
| Abstrakt: |
. More than 50% of hemodialysis patients in our hospital receive empiric vancomycin yearly. Since the local incidence of methicillin-resistant Staphylococcus aureus bacteremia was < 4th%, the frequent use of vancomycin appeared to be primarily due to dosing convenience. We report our retrospective observations comparing the efficacy and safety of vancomycin and/or (beta-lactams in 30 episodes of methicillin susceptible Staphylococcus aureus (MSSA) bacteremia from 1995 to 1998. A strong statistical trend was found between patients treated with vancomycin and/or (beta-lactams in time to defervescence (3.6 vs. 2.9 vs. 1.4 days, p = 0.058). Persistent bacterernia was found in 7 cases initially treated with vancomycin and 1 case treated with (beta-lactam (37% vs. 25%, p > 0.05). There was no difference in the frequency of' vascular access removal, time to bacterial eradication or the incidence of adverse drug reactions. In hemodialysis patients with MSSA bacteremia, (beta-lactam therapy seemed to he associated with a shorter duration of fever. Our observation provides an additional incentive to choose (beta-lactams rather than vancomycin in this setting. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
